Safety of co-vaccination with 23-valent pneumococcal polysaccharide vaccine and split influenza virus vaccine in key populations: an active surveillance study in 8 cities of Anhui province

Abstract

ObjectiveTo evaluate the safety of co-vaccination with domestic 23-valent pneumococcal polysaccharide vaccine (PPSV23) and split influenza virus vaccine (sFlu) in key populations aged 3 years and older and to provide a reference for formulating co-vaccination strategies. MethodsThe study participants were 5 502 healthy and unhealthy (with chronic diseases) volunteers (including 2 072 children aged 3 – 0.05). The grades of adverse reactions in the participants of the three age groups were mainly grade 1 and 2. The overall incidence rate of adverse reactions in healthy participants was 2.32% and that in unhealthy participants was 3.15%, without significant difference between the two groups (χ2 = 3.530, P > 0.05). There were no significant differences in the incidence and severity of adverse events between the healthy and unhealthy participants aged 3 – 0.05). ConclusionSimultaneous vaccination with domestic PPSV23 and sFlu has shown good safety in key populations of different ages, health status and simultaneous vaccination with the two vaccines is recommended.

Keywords

• 23-valent pneumococcal polysaccharide vaccine
• split influenza virus vaccine
• simultaneous vaccination
• safety